Overview

Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients

Status:
Completed

Trial end date:
2021-01-10

Target enrollment:

Participant gender:

Summary

We conducted a 3-month, randomized, single-blind study in 102 Egyptian NASH patients who were divided into three groups; group 1 included 34 patients received Vit. E 400 mg twice a day, group 2 included 34 patients received UDCA 250 mg twice a day and group 3 included 34 patients received PTX 400 mg twice daily for 3 months. The following parameters were measured both before and after intervention intake; liver aminotransferases (AST, ALT), cytokine and chemokine (IL6 and CCL2/MPC-1), albumin, total bilirubin, direct bilirubin, total cholesterol, triglyceride, LDL, HDL.

Phase:

Phase 4

Details

Lead Sponsor:

Kafrelsheikh University

Treatments:

alpha-Tocopherol
Pentoxifylline
Tocopherols
Ursodeoxycholic Acid
Vitamin E